CoChat

Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects

Open access
Becker, R. H. A., Stechl, J., Msihid, J., Kapitza, C. · 2014 · Diabetes, Obesity and Metabolism
Cited by 25

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists improve blood glucose control by enhancing glucose‐sensitive insulin release, delaying gastric emptying and reducing postprandial glucagon secretion. The studies reported here investigated the insulin response to an intravenous (iv) glucose challenge after injection of lixisenatide (LIXI) 20 µg or placebo. Methods: Two single‐centre, double‐blind, randomized, placebo‐controlled, single‐dose, crossover studies were performed in healthy subjects ( HS ) and people with type 2 diabetes mellitus ( T2DM ). Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge. Study endpoints included first‐ and second‐phase insulin response, insulin concentration (INS), glucagon response and glucose disposal rate ( K glucose ). LIXI exposure was measured over 12 h. Results: LIXI 20 µg reached maximum concentration after 2 h and resensitized first‐phase insulin secretion by 2.8‐fold in T2DM to rates comparable with those in HS on placebo, and raised second‐phase insulin secretion by 1.6‐fold in T2DM . INS rose correspondingly and glucose disposal was accelerated by 1.8‐fold in T2DM . First‐phase insulin secretion and glucose disposal were also augmented by LIXI in HS , whereas second‐phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short‐lasting rise in glucagon. Otherwise, suppression of glucagon release subsequent to augmentation of insulin release was unaffected in T2DM and in HS . Conclusions: LIXI resensitized the insulin response to an iv glucose challenge in people with T2DM , thereby accelerating glucose disposal to nearly physiological intensity, and did not impair counter‐regulation to low glucose levels by glucagon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12278

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. 10.1111/j.1463-1326.2012.01663.x · DOI · Paper page
  2. 10.1152/physrev.00034.2006 · DOI · Paper page
  3. 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  4. 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
  5. 10.2337/diabetes.51.2007.S109 · DOI · Paper page
  6. 10.1007/s00125-002-0930-6 · DOI
  7. 10.1002/dmrr.198 · DOI · Paper page
  8. 10.2337/diabetes.52.7.1786 · DOI · Paper page
  9. 10.1111/dom.12121 · DOI · Paper page
  10. 10.2337/dc12-2462 · DOI · Paper page
  11. 10.1111/j.1463-1326.2012.01618.x · DOI · Paper page
  12. 10.1016/0169-2607(96)01755-5 · DOI · Paper page
  13. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  14. Rachman J, 1996, Normalization of insulin responses to glucose by overnight infusion of glucagon‐like peptide 1 (7–36) amide in patients with NIDDM, Diabetes, 45, 1524, 10.2337/diab.45.11.1524 · DOI · Paper page
  15. 10.1152/ajpendo.1997.273.5.E981 · DOI · Paper page
  16. 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
  17. 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
  18. 10.1210/jc.2002-021545 · DOI · Paper page
  19. Ratner RE, 2009, Post‐meal pharmacodynamic profile of AVE0010, a once‐daily GLP‐1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract), Diabetologia, 52, S60
  20. Distiller LA, 2008, on behalf of the ACT6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP‐1 agonist AVE0010 in type 2 diabetes patients [Abstract], Diabetes, 57, A154
  21. 10.1016/j.regpep.2013.04.001 · DOI · Paper page
  22. 10.1111/j.1463-1326.2011.01452.x · DOI · Paper page

Cited by

See all 25

Metadata

Authors
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-03-25
Volume
16
Issue
9
Pages
793-800
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2050250967
Cited by
25
References
14
FWCI
3.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.